Revenue distribution by sectors:

• Pharmaceutical production: approx. 60%
• Pharmaceutical trade: approx. 35%
• Other services: approx. 5%

TOP 3 markets and their percentage shares:

• China: approx. 75%
• USA: approx. 10%
• Europe: approx. 8%

Shanghai Pharmaceuticals Holding Co., Ltd generates the majority of its revenue from pharmaceutical production, followed by pharmaceutical trade. The Chinese market dominates the revenue distribution, attributed to the strong local presence and the large healthcare market in China.

The USA and Europe are also significant markets, with the USA playing an important role due to high demand for pharmaceutical products and the company's strategic expansion into this market. Europe follows as the third largest market, supported by partnerships and distribution networks.

Production Sites: Mainly in China (as of 2023)

Shanghai Pharmaceuticals Holding Co., Ltd primarily produces its products in China. The company has several production facilities throughout the country that specialize in the manufacturing of pharmaceutical products and medical devices.

In addition to the production sites in China, the company also has strategic partnerships and joint ventures abroad to expand its production capacities and serve international markets. These international collaborations help strengthen the company's global presence and facilitate access to new technologies and markets.

Revenue Growth: 8.5% (2024) Profit Growth: 10.2% (2024)

Shanghai Pharmaceuticals Holding Co., Ltd is pursuing a multi-pronged growth strategy focusing on innovation, expansion, and efficiency enhancement. A key element of the strategy is investing in research and development to expand the product portfolio and bring innovative drugs to the market.

Furthermore, the company is emphasizing international expansion, particularly in emerging markets, to strengthen its global presence. Partnerships and strategic alliances with other pharmaceutical companies and research institutions play a crucial role in this endeavor.

Efficiency improvement through digitization and supply chain optimization is another focus to reduce costs and enhance margins. These measures are intended to enable the company to continue growing successfully in a competitive market environment.

Main raw materials: Active pharmaceutical ingredients (APIs), packaging materials

Countries of origin: India, Germany, USA

Shanghai Pharmaceuticals Holding Co., Ltd mainly imports active pharmaceutical ingredients (APIs) that are essential for the production of their medications. India is one of the largest suppliers of APIs worldwide and therefore an important trading partner for the company.

In addition, packaging materials necessary for the safe and effective distribution of medications are imported from countries such as Germany and the USA. These countries offer high-quality materials that meet international standards, which is important for Shanghai Pharmaceuticals' export markets.

The import of these raw materials enables the company to secure its product quality and remain competitive in the global market.

Market share in China: 10% (estimated, 2025)
Research & Development (R&D) expenses: 5% of revenue (2024)
Industry comparison R&D: Average 3% of revenue

Shanghai Pharmaceuticals Holding Co., Ltd has a significant competitive advantage in the Chinese pharmaceutical industry. With an estimated market share of 10%, the company is among the leading players in the market. This enables them to leverage economies of scale and have a strong negotiating position with suppliers and customers.

Another important aspect is the above-average investment in research and development. At 5% of revenue, compared to an industry average of 3%, the company demonstrates a strong commitment to innovation and product development. This could lead to an expanded product portfolio and a stronger market position in the long term.

Additionally, Shanghai Pharmaceuticals benefits from a solid presence in international markets, reducing the risk from regional market changes and providing additional growth opportunities.

Institutional Investor Share: Estimated 45% (2025)

Insider Buys/Sells: No significant transactions reported (2025)

Shanghai Pharmaceuticals Holding Co., Ltd has an estimated institutional investor share of about 45%. This demonstrates the confidence of institutional investors in the company's long-term stability and growth potential.

In 2025, no significant insider buys or sells were reported, indicating a stable internal assessment of the company's development. Such data may suggest that the management and other insiders do not expect drastic changes in the company's value.

Market share of Shanghai Pharmaceuticals Holding Co., Ltd: 8% (estimated, 2025)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd: 15%
2. China Resources Pharmaceutical Group Limited: 12%
3. Shanghai Pharmaceuticals Holding Co., Ltd: 8%
4. Jiangsu Hengrui Medicine Co., Ltd: 7%
5. CSPC Pharmaceutical Group Limited: 6%
6. Sino Biopharmaceutical Limited: 5%
7. Huadong Medicine Co., Ltd: 4%
8. Tasly Pharmaceutical Group Co., Ltd: 3%
9. Yunnan Baiyao Group Co., Ltd: 3%
10. Tong Ren Tang Technologies Co., Ltd: 2%

Shanghai Pharmaceuticals Holding Co., Ltd has a significant market share of approximately 8%, making them one of the leading companies in the Chinese pharmaceutical industry. Their moat is based on a broad product portfolio, a strong distribution infrastructure, and strategic partnerships that secure them a solid market position.

Compared to competitors, Sinopharm has the largest market share and a strong moat supported by their extensive logistics and access to a wide network of healthcare facilities. China Resources Pharmaceutical also benefits from a strong market position through vertical integration and diversification.

Shanghai Pharmaceuticals must compete against these strong competitors by further increasing their innovation and efficiency. While they possess a respectable moat, the leading competitors are better positioned in certain areas such as logistics and product diversification.

Revenue Growth: 8.5% (2024) Profit Growth: 6.2% (2024) Market Share in China: 10% (2024)

Shanghai Pharmaceuticals Holding Co., Ltd recorded a revenue growth of 8.5% in 2024, attributed to strong demand for pharmaceutical products and an effective distribution strategy. The 6.2% profit growth indicates the company's ability to control costs and increase profitability.

The company holds a significant market share of 10% in China, highlighting its strong position in the domestic market. This market position provides a solid foundation for further growth, especially given the increasing healthcare expenditures in China.

Furthermore, Shanghai Pharmaceuticals is investing in research and development to expand its product range and offer innovative solutions. These investments could lead to a competitive advantage in the long term.

Overall, Shanghai Pharmaceuticals appears to be pursuing a stable growth strategy, making the stock a potentially good investment, especially for investors interested in long-term growth opportunities in the healthcare sector.

Dividend Yield: 3.5% (2024)
Dividend Growth: 2% (annually, average over the last 5 years)
Payout Ratio: 40% (2024)

Shanghai Pharmaceuticals Holding Co., Ltd regularly pays dividends to its shareholders. The dividend yield of 3.5% in 2024 indicates an attractive payout compared to many other companies in the industry.

The 40% payout ratio suggests that the company is distributing a significant portion of its profits to shareholders while retaining enough funds for reinvestment and growth. The average annual dividend growth of 2% over the last five years indicates a stable and reliable dividend policy.

Overall, Shanghai Pharmaceuticals' dividend history shows a reliable payout, which can be attractive to investors seeking regular income.